neuromyelitis


Also found in: Medical, Encyclopedia.
Related to neuromyelitis: neuromyelitis optica
Translations

neu·ro·my·e·li·tis

n. neuromielitis, infl. de los nervios de la espina dorsal.
References in periodicals archive ?
M2 PRESSWIRE-September 4, 2019-: Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
Inebilizumab is initially being developed as a first-line monotherapy treatment for neuromyelitis optica spectrum disorder, or NMOSD, a rare condition affecting the optic nerve, spinal cord and brain stem, invariably leading to irreversible blindness and paralysis.
The purpose of the Walk-Run-N-Roll is to raise funds and awareness for the rare neuroimmune disorders addressed by the Transverse Myelitis Association, including acute disseminated encephalomyelitis, acute flaccid myelitis, MOG antibody-associated disease, neuromyelitis optica spectrum disorder, optic neuritis and transverse myelitis.
(NASDAQ: ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) have been accepted for presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11 to 13, 2019.
* Received 3 regulatory approvals - SOLIRIS[R] (eculizumab) for adults with neuromyelitis optica spectrum disorder (NMOSD) in the U.S., and ULTOMIRIS[R] (ravulizumab-cwvz) for adults with paroxysmal nocturnal hemoglobinuria (PNH) in Japan and the EU
- The European Medicines Agency Committee for Medicinal Products for Human Use has issued a positive opinion to extend the current marketing authorization of Soliris (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody positive with a relapsing course of the disease, US-based Alexion Pharmaceuticals, Inc.
[ClickPress, Fri Jul 19 2019] This research report titled " Neuromyelitis optica spectrum disorder (NMOSD)-Market Insights, Epidemiology and Market " Forecast-2028 has been added to the wide online database managed by Market Research Hub (MRH).
The US Food and Drug Administration (FDA) has approved United States-based Alexion Pharmaceuticals' (NASDAQ: ALXN) Soliris intended to treat adults with neuromyelitis optica spectrum disorder (NMOSD), a rare and severe autoimmune disease, who are anti-aquaporin-four antibody positive, it was reported on Friday.
Food and Drug Administration has approved Soliris (eculizumab) injection as the first treatment for neuromyelitis optica spectrum disorder (NMOSD), the agency announced Thursday.
Global Banking News-June 28, 2019-FDA clears first treatment for neuromyelitis optica spectrum disorder
Food and Drug Administration approved Soliris injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder, or NMOSD, in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.